

个人中心

[主菜单](#)
[我的伦理申请](#)
[我的订单](#)
[我的细胞订单](#)
[我的项目](#)
[我关注的基因](#)
[课题组管理](#)
[订单管理](#)
[费用管理](#)
[伦理申请](#)
[项目管理](#)
[成员管理](#)
[课题组设置](#)
[消息通知](#)
[个人设置](#)
[全部收缩](#)
1.Administrative Data.
*** 1.1.Principal Investigator Data.**

Other investigators

If you don't belong to CAM-SU GRC, you should cooperate with a PI of CAM-SU GRC who should take responsibility for your experiment. And, "co-principal investigator" refers to your own tutor.

Principal investigator(PI in CAM-SU)	<input type="text"/>		
E-mail	<input type="text"/>		
Office phone	<input type="text"/>	Cell phone	<input type="text"/>

1.2.Co-Principal Investigator Data.

Co-principal investigator	<input type="text"/>		
E-mail	<input type="text"/>		
Office phone	<input type="text"/>	Cell phone	<input type="text"/>

1.3.Other Investigator Data.

Other investigators	E-mail	Office phone	Cell phone	
<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	

*** 1.4.Project Data.**

Project title	<input type="text"/>		
Funding origin (No.)	<input type="text"/>		
Estimated start and end date	<input type="text"/>	-	<input type="text"/>
Please check all that apply	<input type="checkbox"/> New	<input type="checkbox"/> Breeding/maintenance	<input type="checkbox"/> Survival surgery
	<input type="checkbox"/> BrdU labeling	<input type="checkbox"/> Immunization	<input type="checkbox"/> Anesthetize and release(blood collection)
	<input type="checkbox"/> 3 year rewrite	<input type="checkbox"/> Experimental	<input type="checkbox"/> Non-survival surgery
	<input type="checkbox"/> embryo collection	<input type="checkbox"/> Monoclonal antibody production	<input type="checkbox"/> Tumor induction or implantation
	<input type="checkbox"/> Transgenic creation	<input type="checkbox"/> Knockout creation	<input type="checkbox"/> Behavior studies
<input type="checkbox"/> Source of tissues	<input type="checkbox"/> Polyclonal antibody production	<input type="checkbox"/> Other, please specify below: <input type="text"/>	

*** 2.Animal requirements.**

(If more than one strain is required, please add the table below for each strain)

Strain/line	Gender	Age range	Weight range(g)	Other requirement	Number of animals to be used				Number of cages		
					Year 1	Year 2	Year 3	Total	Year 1	Year 2	Y
<input type="text"/>	M	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>

 自动保存(9) 已开启

* 3.Objective/Hypothesis.

Briefly describe in non-technical terms the scientific aims of this project. This is where you will describe the 'what' and 'why' of your protocol. Justify the project in terms of its potential value in advancing scientific knowledge and/or the benefits of the study to human and/or animal health. Provide sufficient information to indicate that the potential new knowledge from the project justifies the use of animals, improvement of animal management or production. Jargon should be avoided or explicitly explained (please define all acronyms)

* 4.Rationale for animal use.

Please list the alternative to animal use and potential harmful procedures, such as less-invasive procedures, other species, isolated organ preparation, cell or tissue culture, or computer simulation.

* 5.Justify the appropriateness of the species/strain selected.

Please indicate what the advantages of the species/strain you choose are, Such as, easy to model, or particular genetic background, or proven susceptibility to particular induction, or expression of particular gene, etc.

* 6.* Statistical analysis.

(The asterisk indicates this is the focus of review. The same below) Insufficient justification of animal numbers will result in protocol rejection. Include the total numbers of animals used in each experiment and over a 3-year period. Identify any statistical analysis used to demonstrate why this number of animals is necessary for this study.

7.Hazardous agents.

Check if hazardous chemicals, toxins, biologicals and radioactive agents are to be used.

(Hazardous agents include, but are not limited to: infectious agents including bacterial, chlamydiae, fungi, rickettsias, viruses, parasites, prions, human blood, body fluids, tissues or cell cultures, recombinant DNA and the creation (but not acquisition) of transgenic animals, mutagenic or teratogenic substances; sterilant or anesthetic gasses. Radioactive agents include: x-rays, lasers, sealed sources and radioisotopes.)

If yes, please attach a separate sop on handling substances, animals and equipment

YFS

自动保存(9) 已开启

If yes, please attach a separate copy on handling substances, animals and equipment. YES

Hazardous agents Category

- Biological/infectious agents
- Recombinant DNA
- Hazardous chemicals
- Radioisotopes
- Select agents[Name of agent(s):

Where will procedures be performed?

Where will animals be housed?

* 8.Will you use CAM-SU GRC SOPs?

Check and attach CAM-SU GRC SOPs (\\172.21.1.188\Share\03 CAM-SU Animal Protocol)
List the Number and title of CAM-SU GRC SOP.

* 9.* Description of experimental design and animal procedures.

Describe the experimental design as it relates to the number of animals indicated in No. 2. Animal requirements. Specify animal procedures including inoculations (sites, substances, dosages and schedules), blood withdrawals (volume, frequency and withdrawal sites), surgical procedures (provide details on separate form), radiation (dosage and schedule), tail biopsies. Euthanasia criteria (tumor size, percentage body weight gain or loss, inability to drink, clinical symptomatology or signs of toxicity) must be specified when administration of tumor cells, biologicals, infectious agents, radiation of toxic chemicals are expected to cause significant symptomatology or are potentially lethal. Use of death as an endpoint must be scientifically justified.

* 10.What is the expected duration of survival after expression of the phenotype?

What is the expected duration of survival after expression of the phenotype?

*** 11.Pain or Distress Category.**

A generally acceptable method of determining whether or not a procedure would be painful is to consider whether it is considered a painful procedure in man. If it is, then appropriate anesthesia or analgesia should be used. CAM-SU GRC currently employs three Pain and Distress Categories C, D, and E (corresponding to the USDA reportable pain categories). Please indicate the type of pain to be experienced with this research.

PAIN CATEGORY C

PAIN CATEGORY D

PAIN CATEGORY E

For E, (must be scientifically justified) please cite references below:

Definitions:

Category C: Includes only procedures that are considered to produce minimal, transient, or no pain or distress in animals when performed by a competent individual. The definition of USDA category C also emphasizes that protocols involve no more than momentary or slight pain or distress and no use of pain-relieving drugs. Examples include: breeding protocols, injections of material in amounts that will not cause adverse reactions by the following routes: IV, SC, IM, IP; gavages, restraint, tail cuts.

Category D: Includes procedures that have the potential to produce pain or distress in animals, but which are performed using appropriate and adequate anesthetics, analgesics, or tranquilizers to alleviate the pain or distress. Examples include: retro-orbital bleeds, cannulation or catheterization of blood vessels or body cavities under anesthesia, surgical procedures under anesthesia such as biopsies, hepatectomies, stroke, spinal injuries with post-op analgesia.

Category E: Includes potentially painful or distressing procedures that are performed without appropriate and adequate anesthesia, analgesia, or tranquilizers; or are not followed with appropriate measures to alleviate pain or distress; or are not amenable to relief by therapeutic measures. Provide written justification of your requirements. E protocols require the prior review and approval of the full IACUC members before they are initiated. Examples: death as an endpoint studies.

*** 12.Release of pain or distress.**

Will the animals experience pain or distress in association with the phenotype expressed or proposed procedures? What are your plans to avoid or alleviate pain? If your animal protocol involves major survival surgery procedure, please state the pain-releasing drug (component, dose, administration method and time-interval) used post-surgery.

YES

*** 13.Method of health treatment and euthanasia.**

Method of health treatment and euthanasia.

Cervical dislocation*(Cervical dislocation are not recommended and if performed must be justified by scientific necessity. Please detail it): _____

Decapitation*(Decapitation are not recommended and if performed must be justified by scientific necessity. Please detail it): _____

Decapitation: (Decapitation are not recommended and if performed must be justified by scientific necessity. Please detail):

Anesthesia overdose*(Specify agent, dose, frequency and administration route): _____

Exsanguinations with anesthesia.

Perfusion under anesthesia.

CO2 (Recommended).

Other method. Please specify below: _____

Please list the health treatment and possible euthanasia in case of the possible animal sickness and failure of protocols.

Retain Carcass for subsequent experiments?

- YES,4℃
 YES,-20℃
 No,Not reserved

*** 14.Training.**

All research personnel must be appropriately qualified to perform their work with animals.

Qualifications should be in the following areas:

*the basic biology of each species of animals used.

*proper handling of species used.

*adequate familiarity with experimental protocol and techniques as well as pre- and post-procedural care including aseptic techniques.

Training Certifications:

Researchers, including facility staff, have the knowledge and skills enumerated above. Trained animal technicians will perform all breeding and/or experimental procedures. List all the person training record of CAM-SU GRC/other facility on this ANIMAL PROTOCOL:

*** 15.IACUC notification:**

IACUC notification:

- Request for immediate subcommittee review and action*
 For report at regular IACUC meeting

提交申请 暂存

联系我们

CommonCompanyName

电子邮件: office@cam-su.org

详细地址: CommonCompanyAddress



版权所有: CommonCompanyNameSuda CommonCompanylcp

技术支持: 南京百迈斯信息科技有限公司

关注我们

